July 18, 2025 -
Pittsburgh, USA – July 18, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced its participation in the National Medical Association (NMA) Annual Convention and Scientific Assembly, being held from July 19-23, 2025, in Chicago, IL. Attendees are invited to
… Read MoreJuly 10, 2025 -
Pittsburgh, USA – July 10, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced the appointment of Dr. Julia Wright, MD, FACP, as its new Chief Medical Officer (CMO). Dr. Wright, an exceptionally respected physician with a distinguished 25-year career
… Read MoreJune 26, 2025 -
Pittsburgh, USA – June 26, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled “The Clinical Utility
… Read MoreJune 21, 2025 -
Pittsburgh, USA – June 21, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, is proud to showcase its presence at the St. Louis Wound & Vascular Symposium, being held today, Saturday, June 21, 2025, in St. Louis, MO. Attendees are invited to experience firsthand
… Read MoreJune 12, 2025 -
Pittsburgh, USA and Taipei, TAIWAN – June 12, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study
… Read MoreJune 4, 2025 -
Pittsburgh, USA – June 4, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM), taking place in New Orleans,
… Read MoreApril 29, 2025 -
Toronto, Canada – April 29, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, and DocNow, an innovative post-acute Electronic Health Record (EHR) platform, today announced their integration for the MolecuLightDX™ device.
This powerful collaboration will
… Read MoreApril 8, 2025 -
Toronto, Canada – April 8th, 2025 – MolecuLight, a global pioneer in point-of-care fluorescence imaging for rapid bacterial detection in wounds, announces its presence at the American Burn Association (ABA) Annual Meeting in Phoenix, AZ, April 8-11. MolecuLight will showcase its innovative fluorescence imaging systems that empower
… Read MoreApril 3, 2025 -
Toronto, Canada – April 3rd, 2025 – A groundbreaking study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders has unveiled a significant relationship between bacterial load and pain in patients with venous leg ulcers (VLUs), showcasing the potential of MolecuLight’s fluorescence imaging technology to
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.